share_log

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

週一生物技術催化劑綜述-當天結束摘要
Benzinga Real-time News ·  2022/08/22 19:14
The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet's (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D). Insulet shares traded in a range of $260.13 to $266.73 on day volume of 200.86 thousand shares versus three months average volume of 476.99 thousand shares, closed regular trading session at $261.89.
美國食品和藥物管理局(FDA)已宣佈批准Insulet納斯達克的OmniPod 5自動胰島素遞送系統(OmniPod 5)適用於兩歲及以上的1型糖尿病(T1D)患者。Insulet的股票當日成交量為200.86萬股,而三個月平均成交量為476.99萬股,收盤時常規交易時段為261.89美元。
Pfizer (NYSE:PFE) and BioNtech SE (NASDAQ:BNTX) have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals...
輝瑞公司(紐約證券交易所股票代碼:PFE)和BioNTech SE納斯達克公司(S...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論